TRPIM-advised accounts join Enveda Series E

Enveda closed a $311 million Series E financing led by Catalio Capital Management, with accounts advised by TRPIM among new participants. The company plans to use the proceeds for clinical development and expansion of its drug-discovery platform. TRPIM’s investment amount was undisclosed.